Treatment of Hypertension
Information source: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
Intervention: chlorothiazide (Drug); Rauwolfia alkaloids (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI) Official(s) and/or principal investigator(s):
Anthony Damato, Affiliation: USPHS Hospital
Richard Thurm, Affiliation: USPHS Hospital
Christfried Urner, Affiliation: USPHS Hospital
John Vaillancourt, Affiliation: USPHS Hospital
J. Warbasse, Affiliation: USPHS Hospital
Robert Wells, Affiliation: USPHS Hospital
Summary
To determine whether the long-term treatment of essential hypertension without significant
target organ disease materially influenced mortality and/or cardiovascular renal morbidity.
Clinical Details
Study design: Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention
Detailed description:
BACKGROUND:
This grant-supported, cooperative, fixed-protocol clinical study was initiated in 1966 and
followed a cooperative study of the treatment of renal hypertension initiated in 1960 to
evaluate the relative efficacy of several recognized drug regimens for reduction of blood
pressure. Six centers (USPHS hospitals) and a coordinating center were involved in the
trial.
DESIGN NARRATIVE:
Randomized, double-blind, fixed sample. Three hundred and eighty nine eligible patients
were assigned to drug therapy consisting of chlorothiazide plus Rauwolfia serpentina or to
placebo.
The study completion date listed in this record was inferred from last publication listed in
the Citations section of this study record.
Eligibility
Minimum age: 21 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Men and women, ages 21-55. Mild essential hypertension (diastolic blood pressure over 90
mm Hg.
Locations and Contacts
Additional Information
Related publications: U.S. Public Health Service Hospitals Cooperative Study Group. Smith WM, et al: Intervention Trial in Mild Hypertension. Epidemiology and Control of Hypertension. Paul, O (Ed.), Symposia Specialists, Miami, l975, pp. 46l-483. Smith WM. Mild essential hypertension: benefit of treatment: discussion. Ann N Y Acad Sci. 1978 Mar 30;304:74-80. Smith WM, Edlavitch SA, and Krushat WM: U.S. Public Health Service Hospitals Intervention Trial in Mild Hypertension. Hypertension, Determinants, Complications, and Intervention. Onesti G, and Klimt C, (Eds.), Grune & Stratton, New York, l979, pp. 38l-399. Smith WM: Hypertension--Effectiveness of Early Treatment in Preventing Sequellae. Proceedings of the Eisenhower Medical Center. Preventive Interventions in the Practice of Medicine, Spring, l979, pp. 8l-87. Smith WM, Edlavitch SA, and Krushat WM: Prevention of Stroke in Mild Hypertension: Public Health Service Hospitals Trial. Perspectives in Cardiovascular Research, Vol. 4. Prophylactic Approach to Hypertensive Diseases, Yamori Y, Lovenberg W, and Freis ED, (Eds.), Raven Press, New York, l979, pp. 53-62.
Starting date: April 1966
Last updated: November 25, 2013
|
